Merck & Co: Study Meets Primary Endpoint Hiscr50 At Week 16 For High- And Medium-Dose Tulisokibart
Merck & Co: Study Meets Primary Endpoint Hiscr50 At Week 16 For High- And Medium-Dose Tulisokibart
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Merck & Co: Study Meets Primary Endpoint Hiscr50 At Week 16 For High- And Medium-Dose Tulisokibart